KROS Sep 2024 30.000 put
| Previous Close | 1.3500 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 2.9000 |
| Strike | 30.00 |
| Expire Date | 2024-09-20 |
| Day's Range | 1.3500 - 1.3500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2 |
GlobeNewswireKeros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. “Keros remaine
Simply Wall St.Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?
Key Insights Keros Therapeutics' estimated fair value is US$93.42 based on 2 Stage Free Cash Flow to Equity Current...
- GlobeNewswire
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for KER-050 (elritercept) for
